Liquid pharmaceutical formulations comprising 3,7-diazabicyclo 3,3,1 nonane compounds for the treatment and/or prophylaxis of arrhythmic events in human patients, the formulations being suitable for two- step administration of two continuous administration phases, uses of the formulations and the pharmaceutical products and/or packages containing them

摘要

A method of using 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation or flutter to normal sinus rhythm in humans, as well as related methods and pharmaceutical products or packages.